{
  "objCls" : "Guideline",
  "@id" : "https://api.pharmgkb.org/data/guideline/PA166105003",
  "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
  "id" : "PA166105003",
  "name" : "CPIC Guideline for allopurinol and HLA-B",
  "groups" : [ {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://api.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128786",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128786",
    "name" : "Absent ",
    "annotations" : [ {
      "id" : 1445583358,
      "text" : "Low or reduced risk of allopurinol-induced SCAR",
      "textHtml" : "<p>Low or reduced risk of allopurinol-induced SCAR</p>",
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "resource" : "Guideline Tags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925"
      }
    }, {
      "id" : 1445583357,
      "text" : "Low or reduced risk of allopurinol SCAR (absence of *58:01 alleles (reported as \"negative\" on a genotyping test))",
      "textHtml" : "<p>Low or reduced risk of allopurinol SCAR (absence of *58:01 alleles (reported as \"negative\" on a genotyping test))</p>",
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "resource" : "Guideline Tags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927"
      }
    }, {
      "id" : 1445583359,
      "text" : "Use allopurinol per standard dosing guidelines.",
      "textHtml" : "<p>Use allopurinol per standard dosing guidelines.</p>",
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "resource" : "Guideline Tags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928"
      }
    } ],
    "genotypes" : [ "HLA-B:Other/Other" ],
    "strength" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501930",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501930,
      "resource" : "Guideline Strength",
      "term" : "Strong",
      "termId" : "guidelineStrength:981501930"
    }
  }, {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://api.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128787",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128787",
    "name" : "Present",
    "annotations" : [ {
      "id" : 1445583361,
      "text" : "Significantly increased risk of allopurinol-induced SCAR",
      "textHtml" : "<p>Significantly increased risk of allopurinol-induced SCAR</p>",
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "resource" : "Guideline Tags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925"
      }
    }, {
      "id" : 1445583360,
      "text" : "Significantly increased risk of allopurinol SCAR (presence of at least one *58:01 allele (reported as \"positive\" on a genotyping test))",
      "textHtml" : "<p>Significantly increased risk of allopurinol SCAR (presence of at least one *58:01 allele (reported as \"positive\" on a genotyping test))</p>",
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "resource" : "Guideline Tags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927"
      }
    }, {
      "id" : 1445583362,
      "text" : "Allopurinol is contraindicated.",
      "textHtml" : "<p>Allopurinol is contraindicated.</p>",
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "resource" : "Guideline Tags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928"
      }
    } ],
    "genotypes" : [ "HLA-B:*58:01/*58:01", "HLA-B:*58:01/Other" ],
    "strength" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501930",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501930,
      "resource" : "Guideline Strength",
      "term" : "Strong",
      "termId" : "guidelineStrength:981501930"
    }
  } ],
  "history" : [ {
    "id" : 1183699762,
    "date" : "2012-10-17T00:00:00-07:00",
    "type" : "create"
  }, {
    "id" : 1183704552,
    "date" : "2014-02-07T09:31:09.140-08:00",
    "type" : "approve"
  }, {
    "id" : 1444841843,
    "date" : "2015-06-11T15:10:54.200-07:00",
    "description" : "Published update",
    "type" : "update"
  }, {
    "id" : 1444841850,
    "date" : "2015-06-12T08:50:16.155-07:00",
    "type" : "update"
  } ],
  "relatedChemicals" : [ {
    "objCls" : "Chemical",
    "@id" : "https://api.pharmgkb.org/data/chemical/PA448320",
    "@context" : "https://www.pharmgkb.org/jsonld/chemical.jsonld",
    "id" : "PA448320",
    "name" : "allopurinol",
    "version" : 4
  } ],
  "relatedGenes" : [ {
    "objCls" : "Gene",
    "@id" : "https://api.pharmgkb.org/data/gene/PA35056",
    "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
    "id" : "PA35056",
    "symbol" : "HLA-B",
    "name" : "major histocompatibility complex, class I, B",
    "version" : 38
  } ],
  "source" : "CPIC",
  "summary" : "Allopurinol is contraindicated in individuals with the HLA-B*58:01 variant allele (\"HLA-B*58:01-positive\") due to significantly increased risk of allopurinol-induced SCAR.",
  "summaryHtml" : "<p>Allopurinol is contraindicated in individuals with the HLA-B*58:01 variant allele (\"HLA-B*58:01-positive\") due to significantly increased risk of allopurinol-induced SCAR.</p>",
  "summaryMarkdown" : {
    "id" : 1447981950,
    "html" : "<p>Allopurinol is contraindicated in individuals with the HLA-B*58:01 variant allele (&quot;HLA-B*58:01-positive&quot;) due to significantly increased risk of allopurinol-induced SCAR.</p>\n",
    "internalLinks" : [ ],
    "markdown" : "Allopurinol is contraindicated in individuals with the HLA-B*58:01 variant allele (\"HLA-B*58:01-positive\") due to significantly increased risk of allopurinol-induced SCAR.",
    "pmids" : [ ],
    "relatedObjects" : [ ],
    "rsids" : [ ]
  },
  "terms" : [ {"@id":"https://api.pharmgkb.org/data/ontologyTerm/cpicStatus/cpicStatus:1183847844","@context":"https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":1183847844,"resource":"CPIC Status","term":"A","termId":"cpicStatus:1183847844"} ],
  "text" : "h3. January 2016\r\n_Accepted article preview online June 2015_\r\n\r\nThe 2015 update of CPIC guidelines regarding allopurinol has been published in _Clinical Pharmacology and Therapeutics_.  Recent literature was reviewed and there is *no new evidence that would change the original guidelines. Therefore, the dosing recommendations in the original publication remain clinically current*. \r\n* Download and read:\r\n**  [Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing: 2015 update |^CPIC_allopurinol_update_2015.pdf] \r\n** [2015 supplement|^ CPIC_allopurinol_update_supplement_2015.pdf]. \r\n\r\nh3. February 2013\r\n_Advanced online publication December 2012_\r\n* Guidelines regarding the use of pharmacogenomic tests in dosing for allopurinol have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium [(CPIC)|/contributors/consortia/cpic_profile.jsp].\r\n* These guidelines are applicable to:\r\n** adults\r\n* Excerpt from the 2013 allopurinol dosing guidelines:\r\n** \"Allopurinol is the most commonly used drug for the treatment of hyperuricemia and gout; however, allopurinol is also one of the most common causes of severe cutaneous adverse reactions (SCAR), which includes drug hypersensitivity syndrome, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). A variant allele of the human leukocyte antigen-B, HLA-B*5801, associates strongly with allopurinol-induced SCAR. We have summarized evidence from the published literatures and develop peer-reviewed guidelines for allopurinol use based on HLA-B genotype.\"\r\n* Download and read:\r\n**  [Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing |^CPIC_HLAB-Allopurinol.pdf] \r\n** [2013 supplement|^ CPIC_HLAB-Allopurinol_Supplemental_Material.pdf]. \r\n\r\nh3. Table 1: Recommended dosing of allopurinol based on _HLA-B_ genotype\r\n\r\n|| Likely Phenotype || Genotypes || Examples of diplotypes || Implications for phenotypic measures   || Recommendations for allopurinol therapy || Classification of recommendation for allopurinol therapy ||\r\n| Low or reduced risk of allopurinol SCAR | Absence of _*58:01_ alleles (reported as \"negative\" on a genotyping test)| *X/*X ^a^|  Low or reduced risk of allopurinol SCAR  |  Use allopurinol per standard dosing guidelines |  Strong |\r\n|Significantly increased risk of allopurinol SCAR | Presence of at least one _*58:01_ allele (reported as \"positive\" on a genotyping test) | _*58:01_/*X ^a^ _*58:01/*58:01_ | Significantly increased risk of allopurinol SCAR| Allopurinol is contraindicated |  Strong |\r\n\r\n_Adapted from Table 2 of the 2013 Guideline Manuscript_\r\n\r\n^a^ *X = any _HLA-B_ genotype other than _*58:01_.\r\n_HLA-B_ = human leukocyte antigen B",
  "textHtml" : "<h3 id=\"January2016\">January 2016</h3><p><em>Accepted article preview online June 2015</em></p><p>The 2015 update of CPIC guidelines regarding allopurinol has been published in <em>Clinical Pharmacology and Therapeutics</em>.  Recent literature was reviewed and there is <strong>no new evidence that would change the original guidelines. Therefore, the dosing recommendations in the original publication remain clinically current</strong>. </p><ul><li>Download and read:<ul><li> <a href=\"/download.do?objCls=Attachment&amp;objId=CPIC_allopurinol_update_2015.pdf\">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing: 2015 update</a> </li><li><a href=\"/download.do?objCls=Attachment&amp;objId=CPIC_allopurinol_update_supplement_2015.pdf\">2015 supplement</a>. </li></ul></li></ul><h3 id=\"February2013\">February 2013</h3><p><em>Advanced online publication December 2012</em></p><ul><li>Guidelines regarding the use of pharmacogenomic tests in dosing for allopurinol have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a href=\"/contributors/consortia/cpic_profile.jsp\">(CPIC)</a>.</li><li>These guidelines are applicable to:<ul><li>adults</li></ul></li><li>Excerpt from the 2013 allopurinol dosing guidelines:<ul><li>\"Allopurinol is the most commonly used drug for the treatment of hyperuricemia and gout; however, allopurinol is also one of the most common causes of severe cutaneous adverse reactions (SCAR), which includes drug hypersensitivity syndrome, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). A variant allele of the human leukocyte antigen-B, HLA-B*5801, associates strongly with allopurinol-induced SCAR. We have summarized evidence from the published literatures and develop peer-reviewed guidelines for allopurinol use based on HLA-B genotype.\"</li></ul></li><li>Download and read:<ul><li> <a href=\"/download.do?objCls=Attachment&amp;objId=CPIC_HLAB-Allopurinol.pdf\">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing</a> </li><li><a href=\"/download.do?objCls=Attachment&amp;objId=CPIC_HLAB-Allopurinol_Supplemental_Material.pdf\">2013 supplement</a>. </li></ul></li></ul><h3 id=\"Table1RecommendeddosingofallopurinolbasedonHLABgenotype\">Table 1: Recommended dosing of allopurinol based on <em>HLA-B</em> genotype</h3><table class=\"table table-striped table-condensed table-hover table-bordered\"><tr><th>Likely Phenotype</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications for phenotypic measures</th><th>Recommendations for allopurinol therapy</th><th>Classification of recommendation for allopurinol therapy</th></tr><tr><td>Low or reduced risk of allopurinol SCAR</td><td>Absence of <em>*58:01</em> alleles (reported as \"negative\" on a genotyping test)</td><td>*X/*X <sup>a</sup></td><td>Low or reduced risk of allopurinol SCAR</td><td>Use allopurinol per standard dosing guidelines</td><td>Strong</td></tr><tr><td>Significantly increased risk of allopurinol SCAR</td><td>Presence of at least one <em>*58:01</em> allele (reported as \"positive\" on a genotyping test)</td><td><em>*58:01</em>/*X <sup>a</sup> <em>*58:01/*58:01</em></td><td>Significantly increased risk of allopurinol SCAR</td><td>Allopurinol is contraindicated</td><td>Strong</td></tr></table><p><em>Adapted from Table 2 of the 2013 Guideline Manuscript</em></p><p><sup>a</sup> *X = any <em>HLA-B</em> genotype other than <em>*58:01</em>.<br/><em>HLA-B</em> = human leukocyte antigen B</p>",
  "textMarkdown" : {
    "id" : 1447981949,
    "html" : "<h3>January 2016</h3>\n<p><em>Accepted article preview online June 2015</em></p>\n<p>The 2015 update of CPIC guidelines regarding allopurinol has been published in <em>Clinical Pharmacology and Therapeutics</em>.  Recent literature was reviewed and there is <strong>no new evidence that would change the original guidelines. Therefore, the dosing recommendations in the original publication remain clinically current</strong>.</p>\n<ul>\n<li>Download and read:\n<ul>\n<li><a href=\"/redirect.jsp?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fallopurinol%2F2015%2F26094938.pdf\" target=\"offsite\">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing: 2015 update </a></li>\n<li><a href=\"/redirect.jsp?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fallopurinol%2F2015%2F26094938-supplement.pdf\" target=\"offsite\">2015 supplement</a>.</li>\n</ul>\n</li>\n</ul>\n<h3>February 2013</h3>\n<p><em>Advanced online publication December 2012</em></p>\n<ul>\n<li>Guidelines regarding the use of pharmacogenomic tests in dosing for allopurinol have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a href=\"/contributors/consortia/cpic_profile.jsp\">(CPIC)</a>.</li>\n<li>These guidelines are applicable to:\n<ul>\n<li>adults</li>\n</ul>\n</li>\n<li>Excerpt from the 2013 allopurinol dosing guidelines:\n<ul>\n<li>&quot;Allopurinol is the most commonly used drug for the treatment of hyperuricemia and gout; however, allopurinol is also one of the most common causes of severe cutaneous adverse reactions (SCAR), which includes drug hypersensitivity syndrome, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). A variant allele of the human leukocyte antigen-B, HLA-B*5801, associates strongly with allopurinol-induced SCAR. We have summarized evidence from the published literatures and develop peer-reviewed guidelines for allopurinol use based on HLA-B genotype.&quot;</li>\n</ul>\n</li>\n<li>Download and read:\n<ul>\n<li><a href=\"/redirect.jsp?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fallopurinol%2F2013%2F23232549.pdf\" target=\"offsite\">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing </a></li>\n<li><a href=\"/redirect.jsp?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fallopurinol%2F2013%2F23232549-supplement.pdf\" target=\"offsite\">2013 supplement</a>.</li>\n</ul>\n</li>\n</ul>\n<h3>Table 1: Recommended dosing of allopurinol based on <em>HLA-B</em> genotype</h3>\n<table class=\"table table-striped table-condensed table-hover table-bordered\">\n<thead>\n<tr><th>Likely Phenotype</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications for phenotypic measures</th><th>Recommendations for allopurinol therapy</th><th>Classification of recommendation for allopurinol therapy</th></tr>\n</thead>\n<tbody>\n<tr><td>Low or reduced risk of allopurinol SCAR</td><td>Absence of <em>*58:01</em> alleles (reported as &quot;negative&quot; on a genotyping test)</td><td>*X/*X <sup>a</sup></td><td>Low or reduced risk of allopurinol SCAR</td><td>Use allopurinol per standard dosing guidelines</td><td>Strong</td></tr>\n<tr><td>Significantly increased risk of allopurinol SCAR</td><td>Presence of at least one <em>*58:01</em> allele (reported as &quot;positive&quot; on a genotyping test)</td><td><em>*58:01</em>/*X <sup>a</sup> <em>*58:01/*58:01</em></td><td>Significantly increased risk of allopurinol SCAR</td><td>Allopurinol is contraindicated</td><td>Strong</td></tr>\n</tbody>\n</table>\n<p><em>Adapted from Table 2 of the 2013 Guideline Manuscript</em></p>\n<p><sup>a</sup> *X = any <em>HLA-B</em> genotype other than <em>*58:01</em>.</p>\n<p><em>HLA-B</em> = human leukocyte antigen B</p>\n",
    "internalLinks" : [ "/contributors/consortia/cpic_profile.jsp" ],
    "markdown" : "## January 2016\r\n\r\n_Accepted article preview online June 2015_\r\n\r\nThe 2015 update of CPIC guidelines regarding allopurinol has been published in _Clinical Pharmacology and Therapeutics_.  Recent literature was reviewed and there is __no new evidence that would change the original guidelines. Therefore, the dosing recommendations in the original publication remain clinically current__. \r\n- Download and read:\r\n  - [Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing: 2015 update ](https://github.com/PharmGKB/cpic-guidelines/raw/master/allopurinol/2015/26094938.pdf) \r\n  - [2015 supplement](https://github.com/PharmGKB/cpic-guidelines/raw/master/allopurinol/2015/26094938-supplement.pdf). \r\n\r\n## February 2013\r\n\r\n_Advanced online publication December 2012_\r\n- Guidelines regarding the use of pharmacogenomic tests in dosing for allopurinol have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium [(CPIC)](/contributors/consortia/cpic_profile.jsp).\r\n- These guidelines are applicable to:\r\n  - adults\r\n- Excerpt from the 2013 allopurinol dosing guidelines:\r\n  - \"Allopurinol is the most commonly used drug for the treatment of hyperuricemia and gout; however, allopurinol is also one of the most common causes of severe cutaneous adverse reactions (SCAR), which includes drug hypersensitivity syndrome, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). A variant allele of the human leukocyte antigen-B, HLA-B*5801, associates strongly with allopurinol-induced SCAR. We have summarized evidence from the published literatures and develop peer-reviewed guidelines for allopurinol use based on HLA-B genotype.\"\r\n- Download and read:\r\n  - [Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing ](https://github.com/PharmGKB/cpic-guidelines/raw/master/allopurinol/2013/23232549.pdf) \r\n  - [2013 supplement](https://github.com/PharmGKB/cpic-guidelines/raw/master/allopurinol/2013/23232549-supplement.pdf). \r\n\r\n## Table 1: Recommended dosing of allopurinol based on _HLA-B_ genotype\r\n\r\n| Likely Phenotype | Genotypes | Examples of diplotypes | Implications for phenotypic measures   | Recommendations for allopurinol therapy | Classification of recommendation for allopurinol therapy |\r\n| --- | --- | --- | --- | --- | --- |\r\n| Low or reduced risk of allopurinol SCAR | Absence of _*58:01_ alleles (reported as \"negative\" on a genotyping test)| *X/*X ^a^|  Low or reduced risk of allopurinol SCAR  |  Use allopurinol per standard dosing guidelines |  Strong |\r\n|Significantly increased risk of allopurinol SCAR | Presence of at least one _*58:01_ allele (reported as \"positive\" on a genotyping test) | _*58:01_/*X ^a^ _*58:01/*58:01_ | Significantly increased risk of allopurinol SCAR| Allopurinol is contraindicated |  Strong |\r\n\r\n_Adapted from Table 2 of the 2013 Guideline Manuscript_\r\n\r\n^a^ *X = any _HLA-B_ genotype other than _*58:01_.\r\n\r\n_HLA-B_ = human leukocyte antigen B",
    "pmids" : [ ],
    "relatedObjects" : [ ],
    "rsids" : [ ],
    "version" : 1
  },
  "variants" : [ ],
  "version" : 11,
  "xrefs" : [ {"@id":"https://api.pharmgkb.org/data/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/","@context":"https://www.pharmgkb.org/jsonld/crossReference.jsonld","id":1447983440,"resource":"Web Resource","xrefId":"https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/"} ]
}